SCHEDULE: Woodline Partners Discloses 7.3% Stake in Pliant Therapeutics

Woodline Partners LP has reported a 7.3% beneficial ownership stake in Pliant Therapeutics, Inc., holding over 4.5 million shares.

Summary

• Woodline Partners LP, an investment adviser, has filed a Schedule 13G indicating beneficial ownership of common stock in Pliant Therapeutics, Inc.
• The reporting person, Woodline Partners LP, holds 4,504,817 shares of Pliant Therapeutics' common stock.
• This ownership represents 7.3% of the total outstanding common stock of Pliant Therapeutics, Inc.
• The percentage is calculated based on 61,388,154 shares outstanding as of August 1, 2025, as reported in the Company's Form 10-Q.
• Woodline Partners LP has sole voting power and sole dispositive power over all 4,504,817 shares.
• The shares are held by Woodline Master Fund LP, for which Woodline Partners LP acts as the investment adviser.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive institutional stake by Woodline Partners LP is generally viewed positively as it signals investor confidence and interest in Pliant Therapeutics. While not an activist stake, it adds to the company's institutional ownership base.

Positives

• Significant institutional investment by Woodline Partners LP, an investment adviser, indicates confidence or strategic interest in Pliant Therapeutics, Inc.
• The acquisition of shares was made in the ordinary course of business, suggesting a standard investment rather than an activist stance.

Negatives

• The filing itself does not present any negative information regarding Pliant Therapeutics, Inc.

Risks

• The filing does not detail specific risks related to Pliant Therapeutics, Inc. beyond the inherent risks of investing in common stock.

Future Outlook

The Schedule 13G filing does not contain any forward-looking statements or guidance from Pliant Therapeutics, Inc. or Woodline Partners LP regarding the issuer's future performance.

Management Comments

• Woodline Partners LP certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates a significant institutional investor, Woodline Partners LP, has taken a passive stake in Pliant Therapeutics, Inc., a common occurrence in the biotechnology sector where specialized funds often invest in promising companies. Such disclosures can signal increased investor interest in the company's pipeline or market position.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a new large shareholder may influence future investor relations strategies, though the stake is declared passive.

Key Dates

Recommendation

The filing indicates a significant institutional investor has taken a passive stake, which is generally a positive signal of confidence. However, a Schedule 13G filing alone does not provide enough fundamental information about Pliant Therapeutics' operations, financials, or future prospects to warrant a 'buy' or 'sell' recommendation. It primarily signals institutional interest, suggesting investors should 'hold' and monitor for further developments or conduct deeper due diligence.

Keywords

Pliant Therapeutics, Woodline Partners, PLRX, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Investment Adviser, Biotechnology